2025
Extended Treatment Duration of Artemether‐Lumefantrine in Ugandan Children with HIV on Efavirenz‐Based Antiretroviral Therapy: A Randomized Controlled Pharmacokinetic and Pharmacodynamic Trial
Whalen M, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Hoffmann T, Aweeka F, Parikh S, Mwebaza N. Extended Treatment Duration of Artemether‐Lumefantrine in Ugandan Children with HIV on Efavirenz‐Based Antiretroviral Therapy: A Randomized Controlled Pharmacokinetic and Pharmacodynamic Trial. The Journal Of Clinical Pharmacology 2025 PMID: 39853752, DOI: 10.1002/jcph.6193.Peer-Reviewed Original ResearchDesbutyl-lumefantrineAntiretroviral therapyEfavirenz-based antiretroviral therapyEfavirenz-based HIV therapyEFV-based antiretroviral therapyEpisodes of malariaHIV co-infectionSignificant reductionExtended treatment durationStatistically significant reductionClinically significant reductionArtemether-lumefantrinePharmacodynamic trialsMalaria episodesPharmacokinetic samplingHIV therapyRandomized studyRecurrence riskDrug interactionsPrimary outcomeRegimensMalariaReinfection riskHIVCo-infection
2020
Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
Hughes E, Mwebaza N, Huang L, Kajubi R, Nguyen V, Nyunt MM, Orukan F, Mwima MW, Parikh S, Aweeka F. Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 83: 140-147. PMID: 31929402, PMCID: PMC7061940, DOI: 10.1097/qai.0000000000002237.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlkynesAnti-HIV AgentsAnti-Retroviral AgentsAntimalarialsArtemetherArtemether, Lumefantrine Drug CombinationArtemisininsBenzoxazinesCyclopropanesDrug CombinationsDrug InteractionsFemaleHIV InfectionsHumansLumefantrineMalariaMalaria, FalciparumPregnancyProspective StudiesUgandaYoung AdultConceptsEfavirenz-based antiretroviral therapyImpact of efavirenzPregnant womenArtemether-lumefantrineMalaria treatmentAntiretroviral therapyEfavirenz therapyIntensive PK evaluationPK exposure parametersPlasmodium falciparum malariaEffect of efavirenzActive metabolite dihydroartemisininAntimalarial exposureClinical responseFalciparum malariaPregnant HIVTreatment regimenNonsignificant reductionClinical pharmacokinetic studiesPK evaluationDrug interactionsLumefantrine concentrationsHIVTreatment durationPK samples
2011
Antimalarial Agents
Parikh S, Lee M, Aweeka F. Antimalarial Agents. Infectious Disease 2011, 561-579. DOI: 10.1007/978-1-61779-213-7_16.Peer-Reviewed Original ResearchOld antimalarial drugMainstay of treatmentCases of malariaDrug-drug interactionsTreatment of malariaImportant infectious diseasesWorld Health OrganizationUncomplicated malariaArtemether-lumefantrinePharmacodynamic interactionsSulfadoxine-pyrimethamineACT drugsCombination therapyPartner drugsProphylactic useArtemisinin drugsDrug interactionsMalaria therapyDrug combinationsOld drugsComplex pharmacologyVirulent human malariaMalaria todayAntimalarial drugsACT exposure
2007
Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa
Parikh S, Ouedraogo J, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa. Clinical Pharmacology & Therapeutics 2007, 82: 197-203. PMID: 17361129, DOI: 10.1038/sj.clpt.6100122.Peer-Reviewed Original ResearchMeSH KeywordsAlkynesAmodiaquineAntimalarialsAryl Hydrocarbon HydroxylasesBenzoxazinesBurkina FasoChromatography, High Pressure LiquidCyclopropanesCytochrome P-450 CYP2C8Dose-Response Relationship, DrugDrug InteractionsEnzyme InhibitorsGenotypeHIV Protease InhibitorsHumansLopinavirMalaria, FalciparumModels, BiologicalPolymorphism, GeneticPyridinesPyrimidinonesPyronesReverse Transcriptase InhibitorsSaquinavirSpectrophotometry, UltravioletSulfonamidesTreatment OutcomeTrimethoprimConceptsAntimalarial drug amodiaquineMalaria-infected patientsAntiretroviral drug efavirenzImportant clinical implicationsAmodiaquine metabolismCYP2C8 genotypeMalaria treatmentN-desethylamodiaquineCYP2C8 variantsCYP2C8 activityCYP2C8 inhibitorsDrug interactionsDefective metabolismClinical implicationsCYP2C8Common polymorphismsDrug efavirenzMetabolismRelevant concentrationsDrugsEfficacyPrimary metabolitesAllele frequenciesToxicitySample size
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply